Eurofins Scientific Nante Stock Earnings Reports

Eurofins reported a strong H1 2026 operational and financial performance despite moderate top-line growth. Key takeaways: organic revenue grew modestly (c. +2.7% H1) with a significant FX headwind (~2.9%) and limited M&A contribution in the period. Management recorded a marked improvement in profitability: adjusted EBITDA margin reached 23.7% (reported EBITDA +190bps YoY) and EPS rose ~29% to EUR 1.55. Free cash flow to the firm improved materially (+46% YoY to EUR 403m) with record cash conversion (47%) and leverage stable (~2.2x). Management attributes margin progress to hub-and-spoke consolidation, IT/digital investments beginning to pay off, reduced separately disclosed items, closure/rationalization of underperforming units and lower exceptional costs. BioPharma remains the main near-term top-line headwind: product testing in parts of Europe, discovery/genomics and some clinical/CDMO contracts were weak or lumpy in H1 (some contracts ended and timing of replacements is uncertain), although the company expects a pickup in H2 and maintains mid-single-digit organic growth medium-term objectives. Strategic capital allocation: divestment of non-core electrical/electronics testing and announced acquisition of Element’s Life Science Testing Services in North America to refocus and strengthen core testing capabilities. CapEx remains elevated for the multi-year hub-and-spoke and IT program (guidance ~EUR 400m p.a.), but management expects this to decline after 2027, enabling continued cash returns (dividend + buybacks) and selective M&A (~EUR 250m revenue p.a. bolt-ons target). Risks/uncertainties include timing of BioPharma contract wins and completion/temporary disruption from IT and site consolidations.